Connection
Bradley Dixon to Thrombotic Microangiopathies
This is a "connection" page, showing publications Bradley Dixon has written about Thrombotic Microangiopathies.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.296 |
|
|
|
-
Ariceta G, Dixon BP, Kim SH, Kapur G, Mauch T, Ortiz S, Vallee M, Denker AE, Kang HG, Greenbaum LA. The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome na?ve to complement inhibitor treatment. Kidney Int. 2021 07; 100(1):225-237.
Score: 0.185
-
Jodele S, Licht C, Goebel J, Dixon BP, Zhang K, Sivakumaran TA, Davies SM, Pluthero FG, Lu L, Laskin BL. Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy. Blood. 2013 Sep 19; 122(12):2003-7.
Score: 0.111